Anti-leishmanial activity of a new formulation of amphotericin B.

Departamento de Parasitología, Universidad Complutense, Madrid, Spain.
Tropical Medicine & International Health (Impact Factor: 2.3). 10/2004; 9(9):981-90. DOI: 10.1111/j.1365-3156.2004.01296.x
Source: PubMed

ABSTRACT The effectiveness of albumin microspheres loaded with amphotericin B was tested in an in vivo model of visceral leishmaniasis using the golden hamster. Free and encapsulated amphotericin B was tested at the dose of 1 mg/kg given by the intracardiac route on days 25, 26 and 27 post-infection (p.i.) to treat animals previously infected with 10(7) stationary promastigotes by the intracardiac route. Encapsulated amphotericin was highly effective against infection causing a reduction of 88.8% and 87.2% in the early stage of infection (day 32 p.i.) and of 66.7% and 54% in a later stage of infection (day 135 p.i.) in liver and spleen parasite load respectively, compared with untreated animals, whereas free amphotericin was inactive. Lymphocyte proliferation was restored together with an increase in CD4(+) subsets in animals treated with encapsulated amphotericin B, but not in those treated with the non-encapsulated compound. Antibody responses did not increase after treatment with encapsulated amphotericin B with antibody levels remaining at base levels for most animals in contrast to those of untreated or treated with free amphotericin, where in most animals the antibody levels sharply increased. This new formulation could be a more economical alternative to liposomes for the treatment of visceral leishmaniasis with amphotericin B.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Targeted cargo delivery systems can overcome drawbacks associated with antileishmanials delivery, by defeating challenges of physiological barriers. Various colloidal particulate systems have been developed in the past; few of them even achieved success in the market, but still are limited in some ways. Areas covered: This review is focused on the pathobiology of leishmaniasis, interactions of particulate systems with biological environment, targeting strategies along with current conventional and vaccine therapies with special emphasis on polymeric nanotechnology for effective antileishmanial cargo delivery. Expert opinion: The problems concerned with limited accessibility of chemotherapeutic cargos in conventional modes to Leishmania-harboring macrophages, their toxicity, and resistant parasitic strain development can be sorted out through target-specific delivery of cargos. Vaccination is another therapeutic approach employing antigen alone or adjuvant combinations delivered by means of a carrier, and can provide preventive measures against human leishmaniasis (HL). Therefore, there is an urgent need of designing site-specific antileishmanial cargo carriers for safe and effective management of HL. Among various colloidal carriers, polymeric particulate systems hold tremendous potential as an effective delivery tool by providing control over spatial and temporal distribution of cargos after systemic or localized administration along with enhancing their stability profile at a comparatively cost-effective price leading to improved chances of commercial applicability.
    Expert Opinion on Drug Delivery 10/2013; DOI:10.1517/17425247.2013.838216 · 4.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this work we introducing a soft magnetic keeper layer to a word line and optimizing the shape of the word line.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amphotericin B remains the preferred choice for leishmanial infection, but has limited clinical applications due to substantial dose limiting toxicities. In the present work, AmB has been formulated in Lipo-polymerosome (L-Psome) by spontaneous self-assembly of synthesized glycol chitosan-stearic acid copolymer. The optimized L-Psome formulation with vesicle size of 243.5±17.9 nm, PDI of 0.168±0.08 and zeta potential of (+) 27.15±0.46 mV with 25.59±0.87% AmB loading was obtained. The field emission scanning electron microscopy (FESEM) and high resolution transmission electron microscopy (HRTEM) images suggest nearly spherical morphology of L-Psome. An in vitro study showed comparatively sustained AmB release (66.082±1.73% within 24 h) and high plasma stability than commercial Ambisome® and Fungizone®, where glycol chitosan content was found to be efficient in preventing L-Psome destabilization in the presence of plasma protein. In vitro and in vivo toxicity studies revealed less toxicity of AmB-L-Psome compared to commercialized Fungizone and AmBisome favored by monomeric form of AmB within L-Psome, observed by UV-visible spectroscopy. Experimental results of in vitro (macrophage amastigote system) and in vivo (Leishmania donovani infected hamsters) illustrated the efficacy of AmB-L-Psome to augment effective antileishmanial properties supported by up-regulation of Th-1 cytokines (TNF-α, IL-12 and IFN-γ) and inducible nitric oxide synthase, and down-regulation of Th-2 cytokines (TGF- β, IL-10 and IL-4), measured by quantitative mRNA analysis by Real Time PCR (RT-PCR). Conclusively, developed L-Psome system could be viable alternative to the current less stable, toxic commercial formulations and developed as highly efficacious drug delivery system.
    Molecular Pharmaceutics 02/2014; 11(3). DOI:10.1021/mp400603t · 4.79 Impact Factor

Full-text (2 Sources)

Available from
Oct 23, 2014